JP2008502584A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008502584A5 JP2008502584A5 JP2006534360A JP2006534360A JP2008502584A5 JP 2008502584 A5 JP2008502584 A5 JP 2008502584A5 JP 2006534360 A JP2006534360 A JP 2006534360A JP 2006534360 A JP2006534360 A JP 2006534360A JP 2008502584 A5 JP2008502584 A5 JP 2008502584A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- agent
- monoclonal antibody
- nucleolin
- chemotherapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 6
- 102100021010 Nucleolin Human genes 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 108010044762 nucleolin Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 231100000196 chemotoxic Toxicity 0.000 claims 4
- 230000002604 chemotoxic effect Effects 0.000 claims 4
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 229930192392 Mitomycin Natural products 0.000 claims 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 3
- 229940127093 camptothecin Drugs 0.000 claims 3
- 229960004562 carboplatin Drugs 0.000 claims 3
- 190000008236 carboplatin Chemical compound 0.000 claims 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 3
- 229960004316 cisplatin Drugs 0.000 claims 3
- 229960004397 cyclophosphamide Drugs 0.000 claims 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 3
- 229960003957 dexamethasone Drugs 0.000 claims 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 3
- 229960004679 doxorubicin Drugs 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 3
- 229960005420 etoposide Drugs 0.000 claims 3
- 229960002949 fluorouracil Drugs 0.000 claims 3
- 229960000485 methotrexate Drugs 0.000 claims 3
- 229960004857 mitomycin Drugs 0.000 claims 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 3
- 229960001756 oxaliplatin Drugs 0.000 claims 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 3
- 229960004618 prednisone Drugs 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 claims 3
- 229960003454 tamoxifen citrate Drugs 0.000 claims 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 3
- 229960004528 vincristine Drugs 0.000 claims 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 3
- 229960004276 zoledronic acid Drugs 0.000 claims 3
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 2
- 231100000167 toxic agent Toxicity 0.000 claims 2
- 239000003440 toxic substance Substances 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/683,480 US7357928B2 (en) | 2002-04-08 | 2003-10-09 | Method for the diagnosis and prognosis of malignant diseases |
| PCT/US2004/033174 WO2005035579A1 (en) | 2003-10-09 | 2004-10-08 | A method for the treatment of maligant diseases by inhibiting nucleolin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008502584A JP2008502584A (ja) | 2008-01-31 |
| JP2008502584A5 true JP2008502584A5 (cg-RX-API-DMAC7.html) | 2009-07-23 |
Family
ID=34435395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006534360A Pending JP2008502584A (ja) | 2003-10-09 | 2004-10-08 | ヌクレオリンを抑制することによる悪性疾患の治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US7357928B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1687337B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008502584A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004279837B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2546730C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2473598T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005035579A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080318889A1 (en) * | 1999-04-08 | 2008-12-25 | Antisoma Research Limited | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
| US7960540B2 (en) * | 1999-04-08 | 2011-06-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
| US20080318890A1 (en) * | 1999-04-08 | 2008-12-25 | Antisoma Research Limited | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
| US20110178161A1 (en) * | 1999-04-08 | 2011-07-21 | Antisoma Research Limited | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
| WO2000061597A1 (en) * | 1999-04-08 | 2000-10-19 | Uab Research Foundation | Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin |
| US8114850B2 (en) * | 1999-04-08 | 2012-02-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
| US7357928B2 (en) | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
| US7541150B2 (en) * | 2002-04-08 | 2009-06-02 | University Of Louisville Research Foundation, Inc | Method for the diagnosis and prognosis of malignant diseases |
| US20040132049A1 (en) * | 2002-06-26 | 2004-07-08 | Bates Paula J. | Method for the detection of apoptosis |
| US7831293B2 (en) * | 2005-05-10 | 2010-11-09 | Advanced Clinical Solutions, Inc. | Method of defining a biological target for treatment |
| CN102539734B (zh) * | 2005-05-12 | 2016-02-03 | 清华大学 | 核仁素辅助的癌症诊断与治疗方法 |
| FR2900341B1 (fr) | 2006-04-27 | 2012-09-14 | Centre Nat Rech Scient | Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer |
| US8481529B2 (en) | 2006-05-16 | 2013-07-09 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Combination cancer chemotherapy |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| US8680019B2 (en) * | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
| US20090176654A1 (en) * | 2007-08-10 | 2009-07-09 | Protelix, Inc. | Universal fibronectin type III binding-domain libraries |
| EP2033655B1 (en) * | 2007-09-04 | 2010-11-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of compounds that inhibit the EF-Tu-nucleolin interaction for preventing or treating tularemia |
| US20090131351A1 (en) * | 2007-11-16 | 2009-05-21 | Antisoma Research Limited | Methods, compositions, and kits for modulating tumor cell proliferation |
| WO2009088837A2 (en) * | 2007-12-31 | 2009-07-16 | The University Of Louisville Research Foundation, Inc. | Methods and products to target, capture and characterize stem cells |
| JP2011511051A (ja) * | 2008-02-05 | 2011-04-07 | アンティソマ リサーチ リミテッド | 生物学的物質およびそれらの使用 |
| BRPI0822661A2 (pt) | 2008-05-22 | 2015-06-30 | Centre Nat Rech Scient | Compostos oticamente puros para eficiência terapêutica melhorada |
| US20110142848A1 (en) * | 2008-08-07 | 2011-06-16 | Chung Leland W K | Anti-beta-2-microglobulin agents and the use thereof |
| KR100998365B1 (ko) * | 2009-06-29 | 2010-12-06 | 압타바이오 주식회사 | 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체 |
| US8737715B2 (en) * | 2009-07-13 | 2014-05-27 | H. Lee Moffitt Cancer And Research Institute, Inc. | Methods and apparatus for diagnosis and/or prognosis of cancer |
| CN108707584A (zh) * | 2009-11-17 | 2018-10-26 | Musc研究发展基金会 | 针对人核仁素的人单克隆抗体 |
| US10030045B2 (en) * | 2010-02-19 | 2018-07-24 | Ohio State Innovation Foundation | Primers and methods for nucleic acid amplification |
| EP2536739A4 (en) * | 2010-02-19 | 2014-02-19 | Univ Ohio State | PRIMER AND METHOD FOR NUCLEIC ACIDIFICATION |
| US20130065227A1 (en) * | 2010-03-04 | 2013-03-14 | Paula J. Bates | Methods of increasing macropinocytosis in cancer cells |
| BR112013008026A2 (pt) | 2010-10-04 | 2016-06-21 | Centre Nat Rech Scient | composições que compreendem ligantes sintéticos multivalentes de nucleolina de superfície e glicosaminaglicanos |
| DK3446714T3 (da) | 2011-06-02 | 2021-05-10 | Univ Louisville Res Found Inc | Anti-nucleolinmiddel-konjugerede nanopartikler |
| WO2013067268A1 (en) * | 2011-11-03 | 2013-05-10 | Tripath Imaging, Inc. | Methods and compositions for preparing samples for immunostaining |
| WO2014187856A1 (en) * | 2013-05-21 | 2014-11-27 | Deutsches Krebsforschungszentrum | Nucleoli disorganisation by knocking down specific alu-repeat containing rna sequences |
| US10857237B2 (en) * | 2015-05-05 | 2020-12-08 | University Of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and MRI and/or X-ray contrast agents |
| CN106405084A (zh) * | 2015-07-31 | 2017-02-15 | 复旦大学附属华山医院 | 核仁素在制备肠癌诊断试剂和治疗药物中的应用 |
| CN106405096A (zh) * | 2015-07-31 | 2017-02-15 | 复旦大学附属华山医院 | 核仁素在制备胃癌诊断试剂和治疗药物中的应用 |
| WO2017156032A1 (en) * | 2016-03-07 | 2017-09-14 | Charlestonpharma, Llc | Anti-nucleolin antibodies |
| US20170338925A1 (en) * | 2016-05-20 | 2017-11-23 | National Taiwan University | Scheduling method of communication system using directional reference signals and related apparatuses using the same |
| JP7034951B2 (ja) | 2016-06-08 | 2022-03-14 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 操作されたウイルスベクターは炎症および免疫応答の誘導を低減する |
| US20190192686A1 (en) | 2016-08-02 | 2019-06-27 | The University Of Louisville Research Foundation, | Targeted nanodroplet emulsions for treating cancer |
| KR20190130138A (ko) * | 2017-03-20 | 2019-11-21 | 캔서 테라퓨틱스 래버러토리즈 인코포레이티드 | 종양 괴사 표적화 조성물 및 방법 |
| WO2019094548A1 (en) | 2017-11-08 | 2019-05-16 | President And Fellows Of Harvard College | Compositions and methods for inhibiting viral vector-induced inflammatory responses |
| CA3153487A1 (en) | 2019-09-10 | 2021-03-18 | University Of Louisville Research Foundation, Inc. | Anti-nucleolin agent-peg-conjugated nanoparticles |
| CA3160812A1 (en) * | 2019-12-24 | 2021-07-01 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Novel anti-fgfr2b antibodies |
| WO2021202425A1 (en) | 2020-03-28 | 2021-10-07 | University Of Louisville Research Foundation, Inc. | Methods of inhibiting or treating coronavirus infection, and methods for delivering an anti-nucleolin agent |
| EP4148132A4 (en) * | 2020-05-07 | 2024-07-03 | Interoligo Corporation | NOVEL NUCLEIC ACID LIGAND AND ITS IDENTIFICATION METHOD |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4474892A (en) | 1983-02-16 | 1984-10-02 | Board Of Trustees Of The Leland Stanford Junior University | Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same |
| US5169774A (en) | 1984-02-08 | 1992-12-08 | Cetus Oncology Corporation | Monoclonal anti-human breast cancer antibodies |
| US4671256A (en) * | 1984-05-25 | 1987-06-09 | Lemelson Jerome H | Medical scanning, monitoring and treatment system and method |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5223427A (en) | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5192660A (en) | 1989-04-24 | 1993-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | ELISA methods for the determination of human platelet derived growth factor (PDGF) dimer forms present in human tissues and fluids |
| US6020145A (en) * | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| AU635008B2 (en) | 1989-12-13 | 1993-03-11 | Genelabs Diagnostics Pte Ltd | Analytical apparatus and method for automated blot assay |
| US6657103B1 (en) * | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5736348A (en) | 1990-11-28 | 1998-04-07 | Fundacao Oswaldo Cruz (Fiocruz) | Method for the immunological diagnosis of Chagas' Disease using recombinant antigens |
| JPH05244988A (ja) | 1992-03-04 | 1993-09-24 | Green Cross Corp:The | 抗組織因子モノクローナル抗体、及びこれによる免疫抑制剤 |
| DE69534347T2 (de) | 1994-01-31 | 2006-05-24 | Trustees Of Boston University, Boston | Bibliotheken aus Polyklonalen Antikörpern |
| JPH07242566A (ja) | 1994-03-01 | 1995-09-19 | Kirin Brewery Co Ltd | 免疫抑制剤 |
| US5691447A (en) * | 1995-03-24 | 1997-11-25 | Tanox Biosystems, Inc. | GC1q receptor, HIV-1 gp120 region binding thereto, and related peptides and targeting antibodies |
| US6096532A (en) | 1995-06-07 | 2000-08-01 | Aastrom Biosciences, Inc. | Processor apparatus for use in a system for maintaining and growing biological cells |
| WO1997022250A1 (en) | 1995-12-15 | 1997-06-26 | Intronn Llc | Therapeutic molecules generated by trans-splicing |
| US6048703A (en) | 1996-11-15 | 2000-04-11 | Cephalon, Inc. | Methods for detecting cell apoptosis |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| EP1007669A1 (en) * | 1997-03-12 | 2000-06-14 | Institut Pasteur | A novel cell surface receptor for hiv retroviruses, therapeutic and diagnostic uses |
| EP1003856A1 (en) | 1997-06-05 | 2000-05-31 | Board of Regents, The University of Texas System | Apaf-1, the ced-4 human homolog, an activator of caspase-3 |
| ATE386802T1 (de) | 1997-06-12 | 2008-03-15 | Novartis Int Pharm Ltd | Künstliche antikörperpolypeptide |
| US6339075B1 (en) | 1997-06-30 | 2002-01-15 | The University Of British Columbia | Use of dextran and other polysaccharides to improve mucus clearance |
| AU6053898A (en) | 1997-08-04 | 1999-02-22 | Burnham Institute, The | A cell-free system of mitochondria-dependent apoptosis, and methods of use ther eof |
| US6325785B1 (en) | 1997-08-14 | 2001-12-04 | Sherwood Services Ag | Sputum trap manifold with nested caps |
| US5925334A (en) | 1997-08-27 | 1999-07-20 | Rubin; Bruce K. | Use of surface active agents to promote mucus clearance |
| US5932475A (en) | 1997-12-12 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Human nucleolin-like protein |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| WO1999053057A1 (en) * | 1998-04-10 | 1999-10-21 | Chugai Research Institute For Molecular Medicine, Inc. | Protein and gene participating in the differentiation of immortalized cells |
| US6306404B1 (en) | 1998-07-14 | 2001-10-23 | American Cyanamid Company | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
| AU6162999A (en) | 1998-09-24 | 2000-04-10 | Promega Corporation | Apoptosis marker antibodies and methods of use |
| WO2000061597A1 (en) | 1999-04-08 | 2000-10-19 | Uab Research Foundation | Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin |
| CA2363984A1 (en) | 1999-04-15 | 2000-10-26 | Merck Frosst Canada & Co. | Antibodies that recognize app cleaved by caspases and methods of use |
| US6165786A (en) | 1999-11-03 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Antisense modulation of nucleolin expression |
| US7070924B1 (en) | 1999-11-08 | 2006-07-04 | Eisai Co., Ltd. | Method of detecting cell death and detection reagent |
| JP2001213804A (ja) | 2000-01-31 | 2001-08-07 | Chugai Pharmaceut Co Ltd | 抗組織因子抗体の複合体 |
| AU2001245793A1 (en) | 2000-03-16 | 2001-09-24 | Cold Spring Harbor Laboratory | Methods and compositions for rna interference |
| AU2001249622B2 (en) | 2000-03-30 | 2007-06-07 | Massachusetts Institute Of Technology | RNA sequence-specific mediators of RNA interference |
| US20020006448A1 (en) | 2000-06-01 | 2002-01-17 | Yuanjin Tao | Compositions and methods for treating back and leg discomfort |
| HK1052301A1 (zh) | 2000-06-02 | 2003-09-11 | University Of Connecticut Health Center | α(2)巨球蛋白与抗原分子的复合物作免疫治疗用途 |
| US20020028488A1 (en) | 2000-06-19 | 2002-03-07 | Sujay Singh | Transgenic avian species for making human and chimeric antibodies |
| DE10037861A1 (de) | 2000-08-01 | 2002-02-14 | Max Delbrueck Centrum | Mittel zur Therapie maligner Erkrankungen |
| US7129084B2 (en) | 2000-08-03 | 2006-10-31 | Therapeutic Human Polyclonals, Inc. | Production of humanized antibodies in transgenic animals |
| EP1873259B1 (en) | 2000-12-01 | 2012-01-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediated by 21 and 22nt RNAs |
| IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| DE60208562T2 (de) | 2001-07-16 | 2006-11-09 | Arla Foods Amba | Verfahren zur herstellung von tagatose |
| AU2002362436A1 (en) | 2001-10-03 | 2003-04-14 | Rigel Pharmaceuticals, Inc. | Modulators of lymphocyte activation and migration |
| WO2003087124A2 (en) | 2002-04-05 | 2003-10-23 | The Burnham Institute | Hmgn2 peptides and related melecules that selectively home to tumor blood vessels and tumor cells |
| US7541150B2 (en) | 2002-04-08 | 2009-06-02 | University Of Louisville Research Foundation, Inc | Method for the diagnosis and prognosis of malignant diseases |
| US7357928B2 (en) | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
| US20040132049A1 (en) | 2002-06-26 | 2004-07-08 | Bates Paula J. | Method for the detection of apoptosis |
| TW200504210A (en) * | 2003-07-30 | 2005-02-01 | Chin-Tarng Lin | A nucleolin antisense inhibiting growth of cancer cell |
| WO2005037323A2 (en) * | 2003-10-10 | 2005-04-28 | University Of Louisville Research Foundation, Inc. | Use of gro to treat or prevent inflammation |
| CN102539734B (zh) * | 2005-05-12 | 2016-02-03 | 清华大学 | 核仁素辅助的癌症诊断与治疗方法 |
| US8540965B2 (en) | 2005-07-29 | 2013-09-24 | Sloan-Kettering Institute For Cancer Research | Single wall nanotube constructs and uses therefor |
| WO2009088837A2 (en) | 2007-12-31 | 2009-07-16 | The University Of Louisville Research Foundation, Inc. | Methods and products to target, capture and characterize stem cells |
| CA2774361C (en) | 2009-10-21 | 2018-04-24 | Health Research, Inc. | Paa nanoparticles for enhancement of tumor imaging |
| US20110111002A1 (en) | 2009-11-12 | 2011-05-12 | Calin Viorel Pop | Transport and delivery of glutathione into human cells using gold nanoparticles |
| CN108707584A (zh) | 2009-11-17 | 2018-10-26 | Musc研究发展基金会 | 针对人核仁素的人单克隆抗体 |
| WO2011119058A2 (en) | 2010-03-22 | 2011-09-29 | Universidade De Coimbra | F3-peptide targeted lipid-based nanoparticles useful for the treatment of angiogenesis-dependent diseases |
| DK3446714T3 (da) | 2011-06-02 | 2021-05-10 | Univ Louisville Res Found Inc | Anti-nucleolinmiddel-konjugerede nanopartikler |
| JP5244988B1 (ja) | 2012-02-20 | 2013-07-24 | 浜松ホトニクス株式会社 | 濃度測定装置および濃度測定方法 |
-
2003
- 2003-10-09 US US10/683,480 patent/US7357928B2/en not_active Expired - Fee Related
-
2004
- 2004-10-08 AU AU2004279837A patent/AU2004279837B2/en not_active Ceased
- 2004-10-08 JP JP2006534360A patent/JP2008502584A/ja active Pending
- 2004-10-08 CA CA2546730A patent/CA2546730C/en not_active Expired - Fee Related
- 2004-10-08 EP EP04785392.4A patent/EP1687337B1/en not_active Expired - Lifetime
- 2004-10-08 WO PCT/US2004/033174 patent/WO2005035579A1/en not_active Ceased
- 2004-10-08 ES ES04785392.4T patent/ES2473598T3/es not_active Expired - Lifetime
-
2008
- 2008-03-04 US US12/041,969 patent/US8029784B2/en not_active Expired - Fee Related
-
2011
- 2011-05-26 US US13/116,319 patent/US8586717B2/en not_active Expired - Fee Related
-
2013
- 2013-10-21 US US14/059,211 patent/US20140220013A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008502584A5 (cg-RX-API-DMAC7.html) | ||
| CA2546730A1 (en) | A method for the treatment of malignant diseases by inhibiting nucleolin | |
| Peng et al. | Epitope molecularly imprinted polymer nanoparticles for chemo-/photodynamic synergistic cancer therapy guided by targeted fluorescence imaging | |
| ES2983582T3 (es) | Composiciones bioortogonales | |
| JP6823067B2 (ja) | 生体直交型組成物 | |
| JP2021120406A5 (ja) | 癌を治療するための組み合わせ物 | |
| JP2021169479A5 (cg-RX-API-DMAC7.html) | ||
| JP2016522261A5 (cg-RX-API-DMAC7.html) | ||
| JP2020512314A5 (cg-RX-API-DMAC7.html) | ||
| SG170730A1 (en) | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 | |
| JP2013518912A5 (cg-RX-API-DMAC7.html) | ||
| JP2019526578A5 (cg-RX-API-DMAC7.html) | ||
| IL195328A0 (en) | Antibodies binding to anionic phospholipids and aminophospholipids and their use in the preparation of pharmaceutical compositions for treating viral infections | |
| EP2301531A3 (en) | Combinations and modes of administration of therapeutic agents and combination therapy | |
| ATE472338T1 (de) | Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs | |
| WO2006079120A3 (en) | Fc-fusion constructs binding to phosphatidylserine and their therapeutic use | |
| JP2017514800A5 (cg-RX-API-DMAC7.html) | ||
| CN108135901A (zh) | 胆管癌的治疗 | |
| JP2009513662A5 (cg-RX-API-DMAC7.html) | ||
| JP2006507308A5 (cg-RX-API-DMAC7.html) | ||
| RU2010151602A (ru) | Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства | |
| Cheng et al. | Zeolitic imidazolate framework-8 encapsulating risedronate synergistically enhances osteogenic and antiresorptive properties for bone regeneration | |
| CN110167596A (zh) | 用于药物递送和稳定化的复合物及其制备方法 | |
| WO2022093800A3 (en) | Carrier particle-drug conjugates, self-immolative linkers, and uses thereof | |
| EA200802350A3 (ru) | Система доставки лекарств |